Top Stories
The US pharma had paid $100 million upfront in 2023 to acquire the anti-CD33 antibody-enabled GSPT1 degrader, which it was testing in patients with acute myeloid leukaemia.
The company also raised $225 million in a concurrent private placement.
After years of stalled pricing talks with AstraZeneca and Daiichi Sankyo, the recommendation follows changes introduced under the UK-US Pharmaceutical Pricing Agreement.
The Phase III CELESTIMO trial hits its primary endpoint, setting up full approval of the CD20/CD3 T-cell engaging bispecific antibody and potentially moving it into earlier lines of treatment.
The move is designed to speed work on NOR-101, a half-life extended anti-IL-13/IL-18 bispecific antibody designed to inhibit both the type 2 and non-type 2 inflammation.
Conference News
FirstWord hosted an expert call this week with a leading European KOL to discuss Phase II data for long-acting anti-TSLP mAbs, Upstream Bio’s verekitug and Windward Bio’s WIN378, presented at the European Respiratory Society (ERS) congress in Barcelona.
Scholar Rock's Isembyld entry pointScholar Rock crossed the FDA finish line with Isembyld (apitegromab-mstn) after a year-long delay due to manufacturing issues. Now indicated for patients aged 2 and ...
FirstWord will be speaking with a leading expert about Phase III data for Cullinan and Otsuka's zipalertinib and J&J's Rybrevant, and how these and other EGFR inhibitors will be used in a biomarker-defined subset of NSCLC.
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based...
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
